RESUMEN
INTRODUCTION: There is little evidence regarding the safety and efficacy of the combination of abemaciclib plus radiotherapy (RT). The majority of studies investigated the combination of RT with Palbociclib or Ribociclib reporting that hematological toxicity is common. Given the unique toxicity profile of Abemaciclib with greater gastrointestinal toxicity compared to hematological toxicity, we wanted to evaluate the toxicity of the combination with RT in metastatic breast cancer (BC) patients. METHODS: Patients with histologically proven metastatic or locally advanced BC treated with RT and concurrent Abemaciclib were selected. Toxicity was assessed according to the NCI-CTCAE V4.0. RESULTS: 32 metastatic sites were treated in nineteen patients and analyzed. All patients received Abemaciclib during the RT course. 68% of patients received a full dose of Abemaciclib during RT. 71.9% of patients received a palliative intent (median dose= 30Gy, range= 8-30Gy), 26.3% were treated to 9 oligo-metastatic or oligo-progressive sites of disease with stereotactic body radiotherapy (SBRT) (median dose = 30Gy, range 21-30Gy given in 3-5 fractions Overall the rate of G3 toxicity was 15.7%. The rate of G3 hematological toxicity was 10.6 % (2/19 patients, one G3 neutropenia and one G3 anemia). No patient presented diarrhea, including those treated to RT sites close to the bowel. One patient developed G3 skin toxicity. Pain significantly improved after RT (mean value NRS pre-RT=3.9, SD=3.07; mean value NRS after-RT=0.9, SD= 0.46; p=<0.0001) Conclusion: Abemaciclib and Concomitant RT seem well tolerated showing acceptable toxicity.
RESUMEN
BACKGROUND/AIM: The novel cytidine analog RX-3117, which is activated by uridine-cytidine kinase 2 (UCK2), shows encouraging activity in pancreatic and bladder cancer Phase IIa studies. In this study we highlight the potential role of UCK2 as a biomarker for selecting patients for RX-3117 treatment. PATIENTS AND METHODS: The online genomics analysis and visualization platform, R2, developed by the Oncogenomics department at the AMC (Amsterdam, The Netherlands) was used for in silico UCK2-mRNA correlation with overall survival of pancreatic cancer patients, while UCK2 protein expression was evaluated by immunohistochemistry on pancreatic tumor formalin-fixed-paraffin-embedded sections from independent pancreatic cancer patients. mRNA expression was also determined for SUIT-2, PANC-1 and PDAC-3. Lastly, the drug sensitivity to RX-3117 was investigated using the Sulforhodamine-B cytotoxicity assay. RESULTS: The in silico data showed that a high UCK2-mRNA expression was correlated with a shorter overall survival in pancreatic cancer patients. Moreover, UCK2 protein expression was high in 21/25 patients, showing a significantly shorter mean. Overall Survival (8.4 versus 34.3 months, p=0.045). Sensitivity to RX-3117 varied between 0.6 and 11 µM. CONCLUSION: Pancreatic cancer cells are sensitive to pharmacologically achievable RX-3117 concentrations and UCK2 might be exploited as a biomarker for patient treatment selection.